Childhood Immunization Status (NQF 0038)

Similar documents
Childhood Immunization Status (NQF 0038)

Diabetes: HbA1c Poor Control (NQF 0059)

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Weight Assessment and Counseling for Children and Adolescents (NQF 0024)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Pediatric and adolescent preventive care and HEDIS *

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)

Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Medical Student Immunization Requirements

2017 CMS Web Interface

Childhood Immunization Status

Dear Student, IMMUNIZATION RECORD INSTRUCTIONS

CDC Influenza Technical Key Points February 15, 2018

High Performance Network Quality Criteria for Designation

Dear University of Chicago Student,

PATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures

2017 CMS Web Interface

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

Safety of HPV vaccination: A FIGO STATEMENT

LTCH QUALITY REPORTING PROGRAM

Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)

2018 CMS Web Interface

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

2018 CMS Web Interface

2018 CMS Web Interface

2018 CMS Web Interface

CHILDHOOD IMMUNIZATIONS

2017 CMS Web Interface

2017 CMS Web Interface

Measure Information Form

2018 CMS Web Interface

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

HEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8

The data refer to persons aged between 15 and 54.

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Immunisation and Disease Prevention Policy

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

Osteoporosis Fast Facts

2018 CMS Web Interface

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

2017 CMS Web Interface

Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Proof of residency in East Orange is mandatory (see Residency Requirements)

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

Response to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines

2017 CMS Web Interface

2018 CMS Web Interface

SECTION O. MEDICATIONS

What DO the childhood immunization footnotes reveal? Questions and answers

Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (dtap)

Quest for Quality: Immunizations

2018 CMS Web Interface

Flu Season Key Points ( )

2018 CMS Web Interface

2016 Cross-Cutting Measure Set

Provider Information: Influenza VISs

2017 CMS Web Interface

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

Recommended Health Screenings

Chapter 6: Impact Indicators

CDC Influenza Division Key Points November 7, 2014

Strep Test 87070, 87071, 87081, Pharyngitis (CWP)

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Immunizations are among the most cost effective and widely used public health interventions.

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

RECOMMENDED IMMUNIZATIONS

This information shows what new challenges are likely to require prevention efforts moving forward.

QUALITY AND SAFETY MEASURES UPDATE January 2016

Medicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes

Pediatric Quality Measure Information Sheet 2017

2018 CMS Web Interface

Child and Adult Preventive Care Services

Meaningful Use Roadmap Stage Edition Eligible Hospitals

Communicable Disease & Immunization

Section V: Immunization

Immunization Guidelines for the Use of State Supplied Vaccine April 18, 2013

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Immunization Guidelines For the Use of State Supplied Vaccine July 1, 2011

46825 (260) $UPONT

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.

Preventive care is important at every age. Making good health choices now can boost your health and well-being for a lifetime.

Influenza (Flu) Fact Sheet

Utah s Immunization Rule Individual Vaccine Requirements

School Nurse Regional Update School Year Immunizations COLORADO IMMUNIZATION BRANCH

3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups

Referral Criteria: Inflammation of the Spine Feb

NOTE: The above recommendations must be read along with the footnotes of this schedule.

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

Commonwealth of Kentucky Department for Medicaid Services Division of Program Quality and Outcomes

Transcription:

Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December 31, 20xx Measure Steward Natinal Cmmittee fr Quality Assurance Endrsed by Natinal Quality Frum Descriptin The percentage f children 2 years f age wh had fur diphtheria, tetanus and acellular pertussis (DTaP); three pli (IPV); ne measles, mumps and rubella (MMR); tw H influenza type B (HiB); three hepatitis B (Hep B), ne chicken px (VZV); fur pneumcccal cnjugate (PCV); tw hepatitis A (Hep A); tw r three rtavirus (RV); and tw influenza (flu) vaccines by their secnd birthday. The measure calculates a rate fr each vaccine and tw separate cmbinatin rates. Measure scring Prprtin Measure type Prcess Ratinale This measure mnitrs the apprpriate and timely use f vaccines fr children prir t their secnd birthday. Pediatric vaccines are respnsible fr preventing 10.5 millin diseases per birth chrt in the U.S. and are a cst effective preventive measure. Fr every dllar spent n immunizatins, as many as $29 can be saved in direct and indirect csts. With the develpment and use f vaccines, the prevalence f sme infectius diseases has dramatically reduced; since the beginning f the 20th century, there has been a 99% decline in vaccinepreventable disease mrbidity. Despite the established guidelines and well knwn benefits f vaccinatin, hwever, in 2007, 22.5% f children 19 35 mnths f age had nt received the recmmended immunizatins. General clinical cnsensus ntes that if immunizatin practices ceased, mst infectius diseases currently prevented by vaccinatins wuld reemerge as serius health threats. This measure facilitates effrts tward infectius disease preventin amng a vulnerable subgrup f the ppulatin. Clinical Recmmendatin Statement Current CDC/ACIP Guidelines recmmend infants and tddlers receive the Hepatitis B series, fur DTaP vaccinatins, fur HiB vaccinatins, three IPV vaccinatins, ne MMR vaccinatin, fur pneumcccal cnjugate vaccinatins, and ne varicella vaccinatin. Sme cmbinatin prducts n the market include bth the DTaP and HiB vaccines and shuld nly be administered three times. In these cases, children receive three HiB vaccinatins instead f the fur mentined abve. The recmmendatin is t receive these vaccinatins between birth and 18 mnths f age. The current HEDIS specificatins allw a grace perid by measuring cmpliance with these recmmendatins between birth and age tw.

Reference Definitins CDC. General Recmmendatins n Immunizatin: Recmmendatins f the Advisry Cmmittee n Immunizatin Practices (ACIP). MMWR 2006; 55(RR15);1 48 http://www.cdc.gv/mmwr/preview/mmwrhtml/rr5515a1.htm Table f Cntents Ppulatin criteria Data criteria (QDS Data Elements) Summary calculatin Ppulatin criteria Initial Patient Ppulatin = AND: Patient characteristic: birth date (age) >=1 year and <2 years t capture all patients wh will reach 2 years during the measurement perid ; Denminatr = AND: All patients in the initial patient ppulatin; AND: Encunter: encunter utpatient w/pcp & bgyn ; Numeratr 1= AND: >= 4 cunt(s) f Medicatin administered: DTaP vaccine, different dates, ccurring >=42 OR: Medicatin allergy: DTaP vaccine ; OR: Diagnsis active: encephalpathy ; OR: Diagnsis active: prgressive neurlgical disrder ; Numeratr 2 = Numeratr 3 = AND: >=3 cunt(s) f Medicatin administered: IPV, different dates, ccurring >=42 OR: Medicatin allergy: IPV ; OR: Medicatin allergy: nemycin ; OR:: Medicatin allergy: streptmycin ; OR: Medicatin allergy: plymyxin ;

AND: Medicatin administered: MMR >=1, ccurring <2 years after the Patient OR: AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: > 1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: measles ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: mumps ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: rubella ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: MMR ; OR: Diagnsis active: immundeficiency ;

Numeratr 4 = Numeratr 5 = Numeratr 6 = AND: >=2 cunt(s) f Medicatin administered: HiB, ccurring >=42 days and <2 years after Patient Medicatin allergy: HiB ; AND: OR: >=3 cunt(s) f Medicatin administered: hepatitis B vaccine, ccurring < 2 years after Patient OR: Diagnsis reslved: hepatitis B diagnsis ; OR: Substance allergy: Baker s yeast ; OR: Medicatin allergy: hepatitis B vaccine ; AND: >=1 cunt(s) f Medicatin administered: VZV, ccurring < 2 years after Patient OR: Diagnsis reslved: VZV ; AND NOT OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: VZV ; OR: Diagnsis active: immundeficiency ; Numeratr 7 = Numeratr 8 = AND: >=4 cunt(s) f Medicatin administered: pneumcccal vaccine, ccurring >=42 Medicatin allergy: pneumcccal vaccinatin ; AND: >=2 cunt(s) f Medicatin administered: hepatitis A vaccine, ccurring <2 years after Patient OR: Diagnsis reslved: hepatitis A diagnsis ; AND NOT: Medicatin allergy: hepatitis A vaccine ; Numeratr 9 = AND: >=2 cunt(s) f Medicatin administered: rtavirus vaccine, ccurring >=42 days and <2 years after Patient Medicatin allergy: rtavirus vaccine ;

Numeratr 10 = Numeratr 11 = AND: >=2 cunt(s) f Medicatin administered: influenza vaccine, ccurring >=180 OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: influenza vaccine ; OR: Diagnsis active: immundeficiency ; AND: >= 4 cunt(s) f Medicatin administered: DTaP vaccine, different dates, ccurring >=42 OR: Medicatin allergy: DTaP vaccine ; OR: Diagnsis active: encephalpathy ; OR: Diagnsis active: prgressive neurlgical disrder ; AND: >=3 cunt(s) f Medicatin administered: IPV, different dates, ccurring >=42 OR: Medicatin allergy: IPV ; OR: Medicatin allergy: nemycin ; OR:: Medicatin allergy: streptmycin ; AND: Medicatin administered: MMR >=1, ccurring <2 years after the Patient OR: AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: > 1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: measles ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ;

AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: mumps ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: rubella ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: MMR ; OR: Diagnsis active: immundeficiency ; OR: Medicatin allergy: plymyxin ; AND: >=1 cunt(s) f Medicatin administered: VZV, ccurring < 2 years after Patient OR: Diagnsis reslved: VZV ; AND NOT OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: VZV ; OR: Diagnsis active: immundeficiency ; AND: OR: >=3 cunt(s) f Medicatin administered: hepatitis B vaccine, ccurring < 2 years after Patient

OR: Diagnsis active: hepatitis B diagnsis ; OR: Diagnsis reslved: hepatitis B diagnsis ; OR: Substance allergy: Baker s yeast ; OR: Medicatin allergy: hepatitis B vaccine ; Numeratr 12 = AND: >= 4 cunt(s) f Medicatin administered: DTaP vaccine, different dates, ccurring >=42 OR: Medicatin allergy: DTaP vaccine ; OR: Diagnsis active: encephalpathy ; OR: Diagnsis active: prgressive neurlgical disrder ; AND: >=3 cunt(s) f Medicatin administered: IPV, different dates, ccurring >=42 OR: Medicatin allergy: IPV ; OR: Medicatin allergy: nemycin ; OR:: Medicatin allergy: streptmycin ; AND: Medicatin administered: MMR >=1, ccurring <2 years after the Patient OR: AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: > 1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: measles ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: mumps ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient

Medicatin allergy: measles vaccine ; AND: >1 cunt(s) f Medicatin administered: rubella vaccine, ccurring <2 years after Patient Medicatin allergy: rubella vaccine ; OR: Diagnsis reslved: rubella ; AND: >1 cunt(s) f Medicatin administered: mumps vaccine, ccurring <2 years after Patient Medicatin allergy: mumps vaccine ; AND: >1 cunt(s) f Medicatin administered: measles vaccine, ccurring <2 years after Patient Medicatin allergy: measles vaccine ; OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: MMR ; OR: Diagnsis active: immundeficiency ; OR: Medicatin allergy: plymyxin ; AND: >=1 cunt(s) f Medicatin administered: VZV, ccurring < 2 years after Patient OR: Diagnsis reslved: VZV ; AND NOT OR: Diagnsis active: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis inactive: cancer f lymphreticular r histicytic tissue ; OR: Diagnsis active: asymptmatic HIV ; OR: Diagnsis active: multiple myelma ; OR: Diagnsis active: leukemia ; OR: Medicatin allergy: VZV ; OR: Diagnsis active: immundeficiency ; AND: OR: >=3 cunt(s) f Medicatin administered: hepatitis B vaccine, ccurring < 2 years after Patient OR: Diagnsis reslved: hepatitis B diagnsis ; OR: Substance allergy: Baker s yeast ; OR: Medicatin allergy: hepatitis B vaccine ; AND: >=4 cunt(s) f Medicatin administered: pneumcccal vaccine, ccurring >=42 Medicatin allergy: pneumcccal vaccinatin ;

Exclusins = AND: Nne; Data criteria (QDS Data Elements) Initial Patient Ppulatin = "Patient characteristic: Birth date using birth date cde list befre the beginning f the measurement perid ; Denminatr = All patients in the initial patient ppulatin; Encunter: encunter utpatient w/pcp & bgyn using encunter utpatient w/pcp & bgyn cde list befre r simultaneusly t Numeratr = Medicatin allergy: DTaP using DTaP cde list befre r simultaneusly t the Medicatin allergy: nemycin using nemycin cde list befre measurement end Medicatin allergy: streptmycin using streptmycin cde list befre measurement end Medicatin allergy: plymyxin using plymyxin cde list befre measurement end Diagnsis active: encephalpathy using encephalpathy cde list gruping befre measurement end Diagnsis active: prgressive neurlgical disrder using prgressive neurlgical disrder befre measurement end Diagnsis active: cancer f lymphreticular r histicytic tissue using cancer f lymphreticular r histicytic tissue cde list gruping befre measurement end Diagnsis inactive: cancer f lymphreticular r histicytic disease using cancer f lymphreticular r histicytic tissue cde list gruping befre measurement end Diagnsis active: asymptmatic HIV using asymptmatic HIV cde list gruping befre measurement end Diagnsis active: multiple myelma using multiple myelma cde list gruping befre measurement end Diagnsis active: leukemia using leukemia cde list gruping befre measurement end Medicatin allergy: MMR using MMR cde list <=2 years befre measurement end Medicatin allergy: mumps vaccine using mumps vaccine cde list befre

Medicatin allergy: measles vaccine using measles vaccine cde list befre Medicatin allergy: VZV vaccine using VZV vaccine cde list befre measurement end Medicatin allergy: influenza vaccine using influenza vaccine cde list befre Substance allergy: Baker s yeast using Baker s yeast cde list befre measurement end Medicatin allergy: hepatitis B vaccine using hepatitis B vaccine cde list befre Medicatin allergy: hepatitis A vaccine using hepatitis A vaccine cde list befre Diagnsis reslved: hepatitis A diagnsis using hepatitis A diagnsis gruping cde list befre Medicatin allergy: rtavirus vaccine using rtavirus vaccine cde list befre Medicatin allergy: pneumcccal vaccine using pneumcccal vaccine cde list befre Medicatin allergy: HiB using HiB cde list befre Medicatin administered: DTaP using DTaP cde list befre the measurement end Medicatin administered: IPV using IPV cde list befre the measurement end Diagnsis reslved: measles using measles cde list gruping befre measurement end Diagnsis reslved: mumps using mumps cde list gruping befre measurement end Diagnsis reslved: rubella using rubella cde list gruping befre measurement end "Medicatin administered: MMR using MMR cde list befre the measurement end Medicatin administered: mumps vaccine using mumps vaccine cde list befre the Medicatin administered: measles vaccine using measles vaccine cde list befre the Medicatin administered: rubella vaccine using rubella vaccine cde list befre the "Medicatin administered: HiB using HiB cde list befre the measurement end Medicatin administered: hepatitis B vaccine using hepatitis B vaccine cde list befre the Diagnsis reslved: VZV using VZV cde list gruping befre the measurement end "Medicatin administered: VZV using VZV cde list befre the measurement end Medicatin administered: influenza vaccine using influenza vaccine cde list befre Diagnsis reslved: hepatitis B diagnsis using hepatitis B cde list gruping ;

Diagnsis active: hepatitis B diagnsis using hepatitis B cde list gruping ; "Medicatin administered: hepatitis A vaccine using hepatitis A vaccine cde list befre Medicatin administered: rtavirus vaccine using rtavirus vaccine cde list befre "Medicatin administered: pneumcccal vaccine using pneumcccal vaccine cde list befre Diagnsis active: immundeficiency using immundeficiency cde list gruping befre r simultaneusly t Exclusins = Nne; Summary calculatin Calculatin is generic t all measures: Calculate the final denminatr by adding all that meet denminatr criteria. Subtract frm the final denminatr all that d nt meet numeratr criteria yet als meet exclusin criteria. Nte sme measures d nt have exclusin criteria. The perfrmance calculatin is the number meeting numeratr criteria divided by the final denminatr. Fr measures with multiple patient ppulatins, repeat this prcess fr each patient ppulatin and reprt each result separately. Fr measures with multiple numeratrs, calculate each numeratr separately within each ppulatin using the paired exclusin. Measure set CLINICAL QUALITY MEASURE SET 2011 2012